Influenza - zanamivir, amantadine and oseltamivir (review): final appraisal determination (FAD)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58) and submitted it to the Institute.
The FAD was sent to the formal consultees for this appraisal who had 15 working days to consider whether they wished to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal closed at 5pm on 9th January 2009.
Influenza - zanamivir, amantadine and oseltamivir (review): Final appraisal determination
Influenza - zanamivir, amantadine and oseltamivir (review): Response to consultee, commentator and website comments on the Appraisal Consultation Document - prepared by the Technical Lead, Rebecca Trowman
Influenza - zanamivir, amantadine and oseltamivir (review): Additional scenario analyses carried out by the Assessment Group
Influenza - zanamivir, amantadine and oseltamivir (review): Consultee and commentator comments on the ACD
This page was last updated: 30 March 2010